Autor/in Augustin, M Gooderham, M Blauvelt, Andrew 1 Burge, R 1 Calabro, S 1 Cauthen, A 1 Chavers, S 1 Fakharzadeh, S 1 Goyal, K 1 Kerdel, F A 1 Langholff, W 1 Leonardi, Craig L 1 Maari, C 1 Menter, A 1 Osuntokun, O 1 Papp, K 1 Papp, K A 1 Pariser, D M 1 Polzer, P 1 Reich, K 1 Sofen, H L 1 Spelman, L 1 Yamanaka, K 1 Zhang, L 1 Zhu, B 1 alle zeigenListe einklappen
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12 Papp, K Maari, C Cauthen, A Gooderham, M Spelman, L Yamanaka, K Polzer, P 2020 - Forschungsinformationssystem des UKE
Rapid Improvements in Health-related Quality of Life and Itch with Ixekizumab Treatment in Randomized Phase 3 Trials: Results from UNCOVER-2 and UNCOVER-3 Leonardi, Craig L Blauvelt, Andrew Sofen, H L Gooderham, M Augustin, M Burge, R Zhu, B 2017 - Forschungsinformationssystem des UKE
Drug Survival of Biologic Therapy in a Large, Disease-based Registry of Patients with Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Menter, A Papp, K A Gooderham, M Pariser, D M Augustin, M Kerdel, F A Fakharzadeh, S 2016 - Forschungsinformationssystem des UKE
